二磷酸氨合物(1:1) | 13597-86-9

• 分子结构分类: 无机化合物 - 均质非金属化合物 - 非金属氧阴离子化合物
• 中文名称: 二磷酸氨合物(1:1)
• 英文名称: diammonium pyrophosphate
• 英文别名: Monoammonium pyrophosphate；azanium;phosphono hydrogen phosphate
• CAS: 13597-86-9；13765-35-0；22690-73-9
• 化学式: 2H₃N*H₄O₇P₂
• 分子量: 212.036
• InChiKey: IYNIYQPKWZYHRQ-UHFFFAOYSA-N

物化性质

• 密度：
  1.88g/cm3 at 20℃
• 解离常数：
  9.25 at 25℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.65
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  ammonium hydroxide 、 焦磷酸 以 水 为溶剂， 反应 0.33h， 以247 mg的产率得到二磷酸氨合物(1:1)
  参考文献：
  名称：

  [EN] ORAL PYROPHOSPHATE FOR USE IN REDUCING CALCIFICATION
  [FR] PYROPHOSPHATE ORAL DESTINÉ À ÊTRE UTILISÉ DANS LA RÉDUCTION DE LA CALCIFICATION

  摘要：

  The current invention relates to use of oral pyrophosphate wherein said pyrophosphate is selected from the group consisting of monoarginine pyrophosphate, monolysine pyrophosphate, dipotassium pyrophosphate, bisethanolamine pyrophosphate and bisammonium pyrophosphate for preventing and/or reducing tissue calcification, particularly soft tissue calcification, and/or diseases or disorders characterized by low plasma PPi levels, as, e.g., occurs in chronic kidney disease (CKD), end-stage renal disease (ESRD), generalized arterial calcification of infancy (GACI), Pseudoxanthoma elasticum (PXE), Arterial Calcification Due to Deficiency of CD73 (ACDC), Ehlers-Danlos syndrome, arteriosclerosis obliterans, venous calcifications, crystal deposition disorders, calcification resulting from neurological disorders, calcinosis universalis, calcinosis circumscripta, scleroderma, dermatomyositis, systemic lupus erythematosus, hyperparathyroidism, neoplasms, milk-alkali syndrome, hypervitaminosis D, tumoral calcinosis, hypophosphatemic rickets, ossification of the posterior longitudinal ligament of the spine, myocardial ischemia, joint calcification, heterotropic ossification of traumatized muscle, angioid streaks, diabetes mellitus type I and II, cardiovascular disorder, calciphylaxis, calciphylaxis secondary to chronic kidney disease, calcific uremic arteriolopathy or atherosclerosis.

  公开号：

  WO2022079653A1